Actavis Inc (ACT) 207.90 $ACT
Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
Business Wire - Mon May 05, 8:01AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC"
by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4" , which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is available on the SEC's EDGAR system, and may be accessed at https://www.sec.gov/Archives/edgar/data/15788...59ds4a.htm.
AstraZeneca Nixes New Bid As Pfizer Woos British PM
at Investor's Business Daily - Fri May 02, 1:11PM CDT
British big pharma AstraZeneca (AZN) turned down a second takeover bid from U.S. counterpart Pfizer (PFE) Friday, saying that the $106 billion offer was still too low. Pfizer's stock dropped nearly 2%, while AstraZeneca's held steady on the stock...
Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 11:10AM CDT
Endo (ENDP) beat on earnings in the first quarter.
A Look At World Stocks' Q1: Shire, Actavis, NXP Semi
at Investor's Business Daily - Thu May 01, 4:32PM CDT
Only a few IBD Top World Stocks have so far reported Q1 results. But the trend through Thursday has been very positive. Dublin, Ireland-based Shire (SHPG) retook a 172.37 buy point Thursday after reporting mixed first-quarter results. Earnings swung...
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...]
Avanir Wins Lawsuit, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:39PM CDT
Shares of Avanir (AVNR) soared 45.6% after the the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit in its favor.
Mylan Beats on Earnings, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:17PM CDT
Mylan (MYL) reported lower-than-expected revenues in the first quarter.
Company News for May 01, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu May 01, 9:06AM CDT
Companies in the News are: WLP,TWX,POM,EXC,ACT
Actavis Tops Q1 Earnings & Sales Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:25PM CDT
Actavis (ACT), which will be acquiring Forest Labs in mid-14, will provide updated guidance once the acquisition goes through.
Stocks Narrowly Mixed As Fed Announcement Looms
at Investor's Business Daily - Wed Apr 30, 12:26PM CDT
Stocks turned narrowly mixed ahead of the Fed's policy statement, which will be released at about 2 p.m. ET. The Dow Jones industrial average and the S&P 500 edged up 0.1% each. The Nasdaq pared an earlier 0.8% loss to 0.1%. Volume was tracking lower...
Actavis Q1 Earnings Beat On Generic Cymbalta Surprise
at Investor's Business Daily - Wed Apr 30, 10:10AM CDT
Specialty drug giant Actavis (ACT) beat analyst Q1 estimates Wednesday, but the company warned that Q2 earnings will be lower due to new competition. Actavis stock was up 2.5% in morning trading on the stock market today, near 203. Earnings jumped...
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Why Earnings Season Could Be Great for Actavis (ACT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:30AM CDT
Actavis has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014; Non-GAAP EPS Increases 75% to $3.49
PR Newswire - Wed Apr 30, 6:00AM CDT
Actavis plc (NYSE: ACT) today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013. On a non-GAAP basis, diluted earnings per share for the first quarter 2014 increased to $3.49, compared to $1.99 per diluted share in the first quarter 2013. GAAP earnings per diluted share for the first quarter 2014 were $0.55, compared to a GAAP loss per share of $0.79 in the prior year period.
Pfizer Expects $100 Billion Grab for AstraZeneca to Boost Pipeline and Drop Tax Rate, an Industrial Info News Alert
Marketwire - Wed Apr 30, 5:31AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Despite a host of headaches, including steep patent losses and an industry in continual reorganization, Pfizer Incorporated (NYSE
FE) (New York, New York) has managed to remain one of the world's largest drug companies. With revenues of $51.6 billion in 2013, the company is now intent on spending at least $100 billion to snatch up AstraZeneca plc (NYSE:AZN) (London, England).
Stocks Close to Reporting their Earnings -- Research on Actavis, NYSE Community Bancorp, Hess, and Dominion Resources
PR Newswire - Wed Apr 30, 3:36AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Actavis PLC (NYSE: ACT), NYSE Community Bancorp Inc. (NYSE: NYCB), Hess Corp. (NYSE: HES) and Dominion Resources Inc. (NYSE: D). Full earnings notes on ACT, NYCB, HES and D can be downloaded upon signing up at:
Forest Laboratories
at Investor's Business Daily - Tue Apr 29, 5:42PM CDT
Forest Laboratories (FRX) said Q4 EPS quadrupled to 87 cents, beating views by 43 cents. Revenue climbed 14% to $1.09 bil, above views for $956.19 mil. Shares fell 0.3% to 89.73. Forest is being acquired by Actavis (ACT), which reports results Wed.
Can Hospira (HSP) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 4:10PM CDT
We expect Hospira (HSP) to beat expectations when it reports first quarter 2014 results on Apr 30 before the opening bell.
Stocks Rise In Weak Trade; Twitter Dives After-Hours
at Investor's Business Daily - Tue Apr 29, 4:09PM CDT
Stocks rose Tuesday, but volume was lower than the previous day. The Nasdaq climbed 0.7% for its first gain in three sessions. The Dow Jones industrial average and the S&P 500 each gained 0.5%. Volume in the stock market today fell 18% on the Nasdaq...
Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
Business Wire - Mon May 05, 8:01AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC"
by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4" , which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is available on the SEC's EDGAR system, and may be accessed at https://www.sec.gov/Archives/edgar/data/15788...59ds4a.htm. AstraZeneca Nixes New Bid As Pfizer Woos British PM
at Investor's Business Daily - Fri May 02, 1:11PM CDT
British big pharma AstraZeneca (AZN) turned down a second takeover bid from U.S. counterpart Pfizer (PFE) Friday, saying that the $106 billion offer was still too low. Pfizer's stock dropped nearly 2%, while AstraZeneca's held steady on the stock...
Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 11:10AM CDT
Endo (ENDP) beat on earnings in the first quarter.
A Look At World Stocks' Q1: Shire, Actavis, NXP Semi
at Investor's Business Daily - Thu May 01, 4:32PM CDT
Only a few IBD Top World Stocks have so far reported Q1 results. But the trend through Thursday has been very positive. Dublin, Ireland-based Shire (SHPG) retook a 172.37 buy point Thursday after reporting mixed first-quarter results. Earnings swung...
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...]
Avanir Wins Lawsuit, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:39PM CDT
Shares of Avanir (AVNR) soared 45.6% after the the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit in its favor.
Mylan Beats on Earnings, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:17PM CDT
Mylan (MYL) reported lower-than-expected revenues in the first quarter.
Company News for May 01, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu May 01, 9:06AM CDT
Companies in the News are: WLP,TWX,POM,EXC,ACT
Actavis Tops Q1 Earnings & Sales Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:25PM CDT
Actavis (ACT), which will be acquiring Forest Labs in mid-14, will provide updated guidance once the acquisition goes through.
Stocks Narrowly Mixed As Fed Announcement Looms
at Investor's Business Daily - Wed Apr 30, 12:26PM CDT
Stocks turned narrowly mixed ahead of the Fed's policy statement, which will be released at about 2 p.m. ET. The Dow Jones industrial average and the S&P 500 edged up 0.1% each. The Nasdaq pared an earlier 0.8% loss to 0.1%. Volume was tracking lower...
Actavis Q1 Earnings Beat On Generic Cymbalta Surprise
at Investor's Business Daily - Wed Apr 30, 10:10AM CDT
Specialty drug giant Actavis (ACT) beat analyst Q1 estimates Wednesday, but the company warned that Q2 earnings will be lower due to new competition. Actavis stock was up 2.5% in morning trading on the stock market today, near 203. Earnings jumped...
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Why Earnings Season Could Be Great for Actavis (ACT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:30AM CDT
Actavis has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014; Non-GAAP EPS Increases 75% to $3.49
PR Newswire - Wed Apr 30, 6:00AM CDT
Actavis plc (NYSE: ACT) today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013. On a non-GAAP basis, diluted earnings per share for the first quarter 2014 increased to $3.49, compared to $1.99 per diluted share in the first quarter 2013. GAAP earnings per diluted share for the first quarter 2014 were $0.55, compared to a GAAP loss per share of $0.79 in the prior year period.
Pfizer Expects $100 Billion Grab for AstraZeneca to Boost Pipeline and Drop Tax Rate, an Industrial Info News Alert
Marketwire - Wed Apr 30, 5:31AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Despite a host of headaches, including steep patent losses and an industry in continual reorganization, Pfizer Incorporated (NYSE
FE) (New York, New York) has managed to remain one of the world's largest drug companies. With revenues of $51.6 billion in 2013, the company is now intent on spending at least $100 billion to snatch up AstraZeneca plc (NYSE:AZN) (London, England). Stocks Close to Reporting their Earnings -- Research on Actavis, NYSE Community Bancorp, Hess, and Dominion Resources
PR Newswire - Wed Apr 30, 3:36AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Actavis PLC (NYSE: ACT), NYSE Community Bancorp Inc. (NYSE: NYCB), Hess Corp. (NYSE: HES) and Dominion Resources Inc. (NYSE: D). Full earnings notes on ACT, NYCB, HES and D can be downloaded upon signing up at:
Forest Laboratories
at Investor's Business Daily - Tue Apr 29, 5:42PM CDT
Forest Laboratories (FRX) said Q4 EPS quadrupled to 87 cents, beating views by 43 cents. Revenue climbed 14% to $1.09 bil, above views for $956.19 mil. Shares fell 0.3% to 89.73. Forest is being acquired by Actavis (ACT), which reports results Wed.
Can Hospira (HSP) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 4:10PM CDT
We expect Hospira (HSP) to beat expectations when it reports first quarter 2014 results on Apr 30 before the opening bell.
Stocks Rise In Weak Trade; Twitter Dives After-Hours
at Investor's Business Daily - Tue Apr 29, 4:09PM CDT
Stocks rose Tuesday, but volume was lower than the previous day. The Nasdaq climbed 0.7% for its first gain in three sessions. The Dow Jones industrial average and the S&P 500 each gained 0.5%. Volume in the stock market today fell 18% on the Nasdaq...
